Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Caribou Biosciences, Inc. - Common Stock (NQ:CRBU)

2.490 -0.010 (-0.40%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Caribou Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Caribou Biosciences, Inc. Shareholders are Encouraged to Contact Robbins LLP for Information About the Lead Plaintiff Deadline in the CRBU Class Action
From Robbins LLP
Via GlobeNewswire
Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025
From Caribou Biosciences, Inc.
Via GlobeNewswire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU
From The Rosen Law Firm PA
Via GlobeNewswire
Expert Ratings For Caribou Biosciences
 
Via Benzinga
Caribou Biosciences Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
 
Via Benzinga
Evaluating Caribou Biosciences: Insights From 4 Financial Analysts
 
Via Benzinga
CRBU INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Caribou Biosciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Caribou Biosciences to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Caribou Biosciences, Inc.
Via GlobeNewswire
CARIBOU ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Caribou Biosciences, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Cracking The Code: Understanding Analyst Reviews For Caribou Biosciences
 
Via Benzinga
Expert Ratings For Caribou Biosciences
 
Via Benzinga
Stockholder Notice: Robbins LLP Informs Stockholders of Caribou Biosciences, Inc. of the Class Action Lawsuit
From Robbins LLP
Via GlobeNewswire
Caribou Biosciences Appoints Sri Ryali as Chief Financial Officer
From Caribou Biosciences, Inc.
Via GlobeNewswire
CRBU INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Caribou Biosciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Rosen Law Firm Urges Caribou Biosciences, Inc. (NASDAQ: CRBU) Investors to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences Reports Third Quarter 2024 Financial Results and  Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board
From Caribou Biosciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
Attention Biotech Investors - Stocks To Watch
RBC's Chris McCarthy discusses biotech investor sentiment at the RBC Global Healthcare Conference. Focused on upcoming binary catalysts, McCarthy highlights Agios Pharmaceuticals, Caribou Biosciences,... 
Via Benzinga
3 Underappreciated Stocks That Could 10x in 10 Years
10x stocks are the holy grail of capital investing. So, here are three companies that have the potential to cross that line. 
Via InvestorPlace
CRBU Stock Earnings: Caribou Biosciences Misses EPS, Misses Revenue for Q1 2024
CRBU stock results show that Caribou Biosciences missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.